Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1998

View Archived Issues

Capsazepine attenuates inflammation-induced hyperalgesic responses

Melanotan II effective as a treatment for psychogenic erectile dysfunction

rAd/p21: an effective gene therapy approach for treating lung cancer

OraPharma's periodontal disease Rx enters phase III testing

Adrenergic agents for BPH described by Abbott in patent literature

MRI contrast agents in development at Nycomed Imaging

Antigestagenic steroid esters patented by Schering AG

Amgen describes preparation and use of KGF proteins

New Asta development candidate represents new type of PDE4 inhibitor

F-12682: new 5-HT1B/1D receptor inverse agonist for depression

Interneuron receives U.S. patent protection for stroke Rx

SmithKline Beecham research leads to discovery of potent and selective 5-HT7 antagonists

Potent mGluR1/mGluR5 receptor antagonist presented by Lilly at EFMC symposium

Pierre Fabre describes pharmacological profile of F-11440 -- new high-efficacy 5-HT1A agonist

Novel glucagon receptor antagonist with potential in treating type I/type II diabetes

Aviron's FluMist PLA/ELA deemed nonfilable by FDA; resubmission planned

Wyeth-Lederle researchers discover potential treatment for RSV infection

Scios will copromote SmithKline Beecham's SSRI

Boston Biomedica's newest anti-HIV candidates receive patent protection in U.S.

FDA accepts Dusa's NDA for filing

Inflammatory/immunological disease collaboration initiated by BMS and Molecumetics

Viragen acquires stake in Inflammatics; adds LeukoVAX to pipeline

Cerebrus enters into collaborative agreement with Lilly for CEB-1555

First phase III MS results reported for Novantrone

U.S. patent issues for Cylexin

Maxim enters collaborative agreement with BioNative

Onyx discovers another therapeutic virus for cancer therapy

Hycamtin receives first approval for small cell lung cancer in Switzerland

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....